No Data
Shengnuo Biotech: Third Quarter Report 2024
Third Quarter Report 2024
ChengDu ShengNuo Biotec's Nine-Month Profit Seen to Surge Up to 76%
VOLUNTARY DISCLOSURE ANNOUNCEMENT FOR THE FIRST THREE QUARTERS OF 2024
Another one! Peptide products drive 'hot' performance, Sanuo Biological's net profit for the first three quarters is expected to increase by 76%.
①Peptide active pharmaceutical ingredients and formulation products are selling well, driving Shen Nuo Biotech's net income in the first three quarters to reach as high as 61.1987 million yuan, with the highest year-on-year increase of 75.88%. ②In September of this year, Shen Nuo Biotech signed a GLP-1 peptide active pharmaceutical ingredient supply contract worth up to 0.35 billion yuan, with a performance period until December 31, 2025.
SanNuo Biology (688117.SH): It is expected that the net income in the first three quarters will increase by 43.9% to 75.88% year-on-year.
Gelonghui October 9th | Shengnuo Biotechnology (688117.SH) announced that, according to preliminary calculations by the finance department, the company is expected to achieve a net income attributable to the owners of the parent company of 50.0717 million yuan to 61.1987 million yuan in the first three quarters of 2024, an increase of 15.2755 million yuan to 26.4025 million yuan compared to the same period last year, a year-on-year increase of 43.90% to 75.88%. It is expected that the net profit attributable to the owners of the parent company in the first three quarters of 2024, excluding non-recurring gains and losses, will be 47.6484 million yuan to 58.237 million yuan, compared to the same period last year.
What ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) 30% Share Price Gain Is Not Telling YouNo Data
No Data
